47 matches for your search in the start-up spotlight
rss
Funding will propel Leyden Labs’ non-vaccine intranasal antibody programs to safeguard people from respiratory viruses
03-Feb-2025
Leyden Laboratories B.V. announced it has raised $70M in funding to advance its Mucosal Protection Platform. This non-vaccine approach utilizes broadly protective intranasally administered antibodies to free people from the threat of respiratory viruses, such as influenza and coronaviruses. The ...
Scientists from the Jena start-up nanozoo GmbH and Jena University Hospital present analysis
28-Jan-2025
To track the spread of pathogens such as SARS-CoV-2 in a more targeted manner, anonymized mobile phone data and other metadata (such as zip codes) can be combined with genome data. A systematic evaluation of such combined data pools has now been presented by scientists from the Jena-based ...
Funding will support and accelerate development of next-generation multivalent respiratory virus vaccines
30-Sep-2024
Vicebio Ltd, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, announces a $100 million Series B financing led by TCGX with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio, and participation from UniQuest and founding ...
Another milestone reached: researchers work together with Swiss biotech start-up to further develop the vaccine
29-Feb-2024
Rocketvax AG, together with the German Research Foundation (DFG), has financially supported a study carried out as part of a joint project of the Swiss National Science Foundation (SNSF, National Research Program “Covid-19,” NRP 78) and the German Research Foundation (DFG) “Recoding the ...
New vaccine technology could protect from future Coronaviruses and variants
05-Oct-2023
Studies of a ‘future-proof’ vaccine antigen candidate have shown that just one antigen can be modified to provide a broadly protective immune response in animals, suggesting that a single vaccine with combinations of these novel antigens could protect against an even greater range of current and ...
University of Basel and biotech start-up RocketVax present a vaccine concept that could lead to a new generation of vaccines
25-May-2023
Researchers at the University of Basel have developed a new approach for a vaccine against COVID-19. This vaccine is based on a modified coronavirus that can enter body cells and trigger an effective immune response but cannot multiply in the body. In animal studies, the vaccine effectively ...
Spear Bio is working towards commercializing its first assay, which accurately assesses levels of SARS-CoV-2-neutralizing antibodies in dried-blood spot samples
13-Sep-2022
The Wyss Institute for Biologically Inspired Engineering at Harvard University and Spear Bio, Inc. announced that the Institute’s DNA nanotechnology-driven ultrasensitive SPEAR protein-detection technology has been licensed to the newly formed Boston-based startup. Spear Bio has signed a ...
In-vitro-Diagnostic company Spindiag, a University of Freiburg and Hahn-Schickard spin-off, has been recognized for its research-based development
19-Apr-2022
Spindiag GmbH, together with the University of Freiburg and the Hahn-Schickard-Gesellschaft für angewandte Forschung e.V., was awarded the Technology Transfer Prize 2020 from the German Physical Society (DPG) on April 09, 2022 for the development of the PCR-based rapid test system Rhonda. The ...
A Toronto-based start-up company that partnered for the study, is developing unique UV-LED lighting modules
05-Apr-2022
The same lightbulbs used in offices and public spaces can destroy coronaviruses and HIV, according to a new study from U of T Scarborough. Researchers killed both viruses using UV-LED lights, which can alternate between white light and decontaminating ultraviolet (UV) light. With a cheap ...
A California-based start-up is currently raising funds for human trials, drug development, formulation and mass production
31-Mar-2022
A newly discovered small molecule could be sprayed into people’s noses to prevent COVID-19 illness prior to exposure and provide early treatment if administered soon after infection, according to a study in mice led by Cornell University researchers. The study, published in Nature, employed ...
